IPP Bureau
GEON Performance Solutions acquires Foster Corporation
By IPP Bureau - January 09, 2025
Acquisition expands high-value medical platform
Mitsubishi Tanabe Pharma enters into a sub-licensing agreement for oral spleen tyrosine inhibitor fostamatinib in Taiwan with Kissei Pharmaceutical
By IPP Bureau - January 09, 2025
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
Elinzanetant meets all primary and secondary endpoints in Phase III study OASIS 4 for treatment of vasomotor symptoms caused by breast cancer treatments
By IPP Bureau - January 09, 2025
The study also met all secondary endpoints with a reduction in severity of VMS at weeks 4 and 12, a reduction in frequency of VMS at week 1 as well as improvements in sleep disturbances and menopause related quality of life
ProBioGen expands protein and viral manufacturing to drive continued growth
By IPP Bureau - January 09, 2025
This strategic move aims to address the increasing global demand for biologics, enhancing ProBioGen's ability to support partners from cell line development t
Lilly to establish new global capability centre in Hyderabad
By IPP Bureau - January 09, 2025
Lilly plans to hire approximately more than 1,000 new highly-skilled team members
HMPV update: States advised to strengthen awareness among masses regarding preventive measures
By IPP Bureau - January 08, 2025
Data from IDSP does not indicate any unusual rise in ILI/SARI cases anywhere in the country
Biocon Biologics embarks on a three-stage strategic journey
By IPP Bureau - January 08, 2025
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
Ajooni Biotech to raise Rs. 45 crore through convertible warrants
By IPP Bureau - January 08, 2025
These initiatives will strengthen the company’s capital base, providing financial flexibility for future
Caplin Point receives EIR from FDA with Zero 483 observations
By IPP Bureau - January 07, 2025
The inspection, which is a routine part of the FDA's regulatory oversight, evaluates compliance with Good Manufacturing Practices and other regulatory requirements.
Sentynl Therapeutics receives USFDA acceptance and priority review of new drug application for CUTX-101 product candidate for treatment of Menkes disease
By IPP Bureau - January 07, 2025
Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A
Sai Ramana Ponugoti appointed as CEO, ICH of Piramal Pharma
By IPP Bureau - January 07, 2025
Consequent to this appointment, Sarosh Shetty ceases to be Interim CEO of ICH.
Quality not just a measure, a way of life that drives innovation: Renewable Energy Minister Joshi
By IPP Bureau - January 07, 2025
The cornerstone of the quality ecosystem is the implementation of the Quality Control Orders
1.48 lakh new TB cases identified in the first 30 days of TB Mukt Bharat -100 Days Intensified Campaign
By IPP Bureau - January 07, 2025
Nadda chairs Joint Strategy Meeting with Line Ministries for TB Mukt Bharat Abhiyan- 100-Day Intensified Campaign
Nutraceuticals CDMO manufacturer Crius Group to adopt 100% AI-based project implementation
By IPP Bureau - January 07, 2025
NutrifyGenie AI, a leading AI-driven platform, was integral in designing scientifically differentiated formulations for a multinational client
Zydus inks agreement with CVS Caremark to add Zituvio, Zituvimet and Zituvimet XR to its template formulary
By IPP Bureau - January 07, 2025
These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route
